Submit Your VivopureX™ Research Proposal to Earn a Research Microgrant from Absolute Antibody

Your cutting-edge research deserves cutting-edge recombinant engineered antibody reagents. This is your opportunity to see for yourself how our technology can promote your discoveries.

In vivo research using mouse models is key to the overall understanding of the immune system and an important stop on the road to clinical applications. Our VivopureX™ line of recombinant antibodies is engineered specifically for improved performance in live mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. These species-matched chimeric antibodies consist of a clone’s original antigen-binding variable domain with a mouse constant domain.

With high purity, serum-free manufacturing, and species matching, VivopureX™ antibodies exhibit low immunogenicity. No neutralizing anti-drug-antibodies are induced, reducing adverse anaphylactic reactions and enabling longer experimental timeframes. Additionally, we offer the antibodies in formats mirroring human antibody therapeutics to give researchers the surrogate molecules they need. Antibodies are available against a wide range of key immunotherapy targets, such as PD-1, CTLA-4 and TIGIT, with tailored effector functions and in clinically relevant formats.

Do you have a research idea that isn’t possible with the traditional format of an antibody? Are you tired of the same old limitations of your in vivo experiments? How would you use VivopureX™ recombinant engineered mouse antibodies to empower your in vivo research?

Tell us and you could receive thousands of dollars in antibody reagents. Learn more in our article about how VivopureX™ antibodies facilitate in vivo research and read on to see how you can secure high-quality antibodies for your lab!

Proposal Guidelines

Interested in receiving free VivopureX™ antibodies? Submit your research proposal to marketing@absoluteantibody.com before June 30, 2023 at 11:59 AM EDT. Include “Call for Proposal” in the subject line.

Projects should be feasible and should be able to be completed in 6-12 months from the start of the project. Projects must feature one or more VivopureX™ antibodies. See the full list of available clones and engineered formats here.

Proposals will be judged by the promotional team based on how well they utilize VivopureX™ antibodies from Absolute Antibody, how unique and interesting they are, and their potential to expand knowledge in their respective fields of research. Preference will be given to research projects that would not be possible using the original, hybridoma-derived formats of the antibodies due to immunogenicity and/or unsuitable effector function.

Our ultimate goal is to provide the best possible antibody reagents and bring recombinant technology to all. We hope these microgrants will provide researchers with the opportunity to use recombinant antibodies in place of traditional hybridoma-derived antibodies, enabling exciting new research possibilities. If you have a research project in mind, but would like to discuss which antibody format would be best suited for your experiments, send us a message! Our antibody engineers are available to provide expert advice on how best to use our VivopureX™ reagents in your proposed experimental plan. We want to support researchers with the most effective antibodies to accomplish their research goals.

No more than one proposal may be submitted per person. By entering this competition, participants give consent for information such as their proposal entry, name, and affiliated institution to be posted to Absolute Antibody marketing channels, including channels under our parent company Absolute Biotech. Winners may be contacted during and at the completion of their proposed project to share their results with the Absolute Antibody team. Depending on the results and research next steps, we may be interested in highlighting your completed project via our marketing channels.

Our Microgrant Prizes

  • 1st place prize: VivopureX™ antibodies and relevant isotype controls in retail value of up to $8,000 USD. Limit: up to three (3) different antibody clones, up to three (3) different relevant isotype controls, and a max volume of 100 mg for any reagent.
  • 2nd place prize: VivopureX™ antibodies and relevant isotype controls in retail value of up to $6,000 USD. Limit: up to three (3) different antibody clones, up to three (3) different relevant isotype controls, and a max volume of 100 mg for any reagent.
  • 3rd place prize: VivopureX™ antibodies and relevant isotype controls in retail value of up to $4,000 USD. Limit: up to three (3) different antibody clones, up to three (3) different relevant isotype controls, and a max volume of 100 mg for any reagent.

Note, a relevant isotype control is defined as an Anti-NP or Anti-Fluorescein isotype control that has the same species, same isotype, and same light chain type as the corresponding antibody.

Winners will be announced July 7, 2023 via Absolute Antibody marketing channels.

Power Your In Vivo Research

We believe recombinant engineered antibodies are the way forward, and we are excited to review your submitted research project proposals! Batch-to-batch reproducibility, 100% biological definition, serum-free manufacturing, and endless engineering possibilities make recombinant antibodies and in vivo studies a perfect match. Explore how VivopureX™ antibodies have already powered discoveries and get inspiration for your own project with the below resources. We look forward to seeing your new and creative uses of the VivopureX™ collection.

  • University of Basel research demonstrates that the species-matched mouse-anti-mouse VivopureX™ version of an antibody can deplete CD8+ T-cells more completely and for longer in mice than the original rat form of the antibody.
  • Our research poster illustrates that syngeneic mouse IgG2a Fc Silent™ PD-1 antibodies reduce tumor size in mouse models more effectively than traditional rat monoclonal antibodies.
  • A recent paper from the University Medical Center Utrecht found that our VivopureX™ mouse-anti-mouse Ly-6G antibody was able to deplete neutrophils in mice more efficiently than the original rat Ly-6G antibody.

Latest News

Upcoming Events

Please join us at the following conferences and events. Stop by our booth, or get in touch to arrange a meeting.

See All Dates

Next Event:

PEGS Boston – Booth #312

13-17th May 2024

Boston, Massachusetts

Antibody Humanization to Combat Antimicrobial Resistant Bacteria

Read more

Is Fc Silencing Right for Your Antibody?

Read more